SynthesisWorld journal of surgical oncology2020
Prognostic value of neuron-specific enolase for small cell lung cancer: a systematic review and meta-analysis.
Synthesis in World journal of surgical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Role of serum neuron-specific enolase levels in the early diagnosis and prognosis of sepsis-associated encephalopathy: a systematic review and meta-analysis.Frontiers in neurology · 2024Pooled it
- Blood-based protein biomarkers during the acute ischemic stroke treatment window: a systematic review.Frontiers in neurology · 2024Pooled it
- Prognostic value of pretreatment smoking status for small cell lung cancer: A meta-analysis.Thoracic cancer · 2020Pooled it
- Elevated serum neuron-specific enolase as an indicator of poor chemo-immunotherapy outcomes and reduced CD8-positive lymphocyte infiltration in small-cell lung cancer: a retrospective cohort study.Translational lung cancer research · 2026Article
- Relationship between tumor markers and overall survival in small cell lung cancer: a retrospective cohort study.Journal of thoracic disease · 2026Article
- Prognostic nomogram for extensive-stage small-cell lung cancer in the immunotherapy era: a multicenter study of first-line platinum-etoposide with or without a PD-1/PD-L1 inhibitor.Translational lung cancer research · 2026Article
- Lateral flow immunochromatographic assay (LFIA) for tumor marker detection: technical evolution, clinical translation challenges, and future perspectives.Mikrochimica acta · 2026Review
- Diagnostic value of serum biomarkers for identifying computed tomography abnormalities in male miners.Scientific reports · 2026Article
- Clinical value of ENO2 in serum extracellular vesicles for the diagnosis and prognosis of diffuse large B-cell lymphoma patients.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Label-free immunoassay based on chemiluminescence-functionalized magnetic mesoporous nanoparticles for rapid detection of neuron-specific enolase.Mikrochimica acta · 2025Article
- MRI and FDG PET/CT findings for small cell neuroendocrine carcinoma of the ovary: a case report and literature review.BMC women's health · 2025Review
- Combined CA125, NSE, and multiple inflammatory indices for diagnosis of oral squamous cell carcinoma.Frontiers in oncology · 2025Article
- Long-term survival after combination therapy with atezolizumab in a patient with small-cell lung cancer: a case report.Translational lung cancer research · 2024Article
- Impedimetric Biosensors for the Quantification of Serum Biomarkers for Early Detection of Lung Cancer.Biosensors · 2024Article
- SGLT-2 Inhibitors' and GLP-1 Receptor Agonists' Influence on Neuronal and Glial Damage in Experimental Stroke.Biomedicines · 2024Article
- Unveiling the atlas of associations between 1,400 plasma metabolites and 24 tumors: Mendelian randomization analyses.Translational cancer research · 2024Article
- Small Cell Lung Cancer Neuronal Features and Their Implications for Tumor Progression, Metastasis, and Therapy.Molecular cancer research : MCR · 2024Review
- Development of a Prediction Model and Corresponding Scoring Table for Postherpetic Neuralgia Using Six Machine Learning Algorithms: A Retrospective Study.Pain and therapy · 2024Article
- ENO2 promotes anoikis resistance in anaplastic thyroid cancer by maintaining redox homeostasis.Gland surgery · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeuron-specific enolase (NSE) has become a widely used and easily attainable laboratory assay of small cell lung cancer (SCLC). However, the prognostic value of NSE for SCLC patients remains controversial. The aim of the study was to evaluate the correlation between elevated serum NSE before therapy and survival of SCLC patients.
methodsWe performed a systematic review and meta-analysis. A systematic literature search was conducted in PubMed, Embase, and the Cochrane Central Register from the inception dates to December 2019. Eligible articles were included according to inclusion and exclusion criteria; then, data extraction and quality assessment were performed. The primary outcome was overall survival (OS), and the secondary endpoint was progression-free survival (PFS).
resultsWe identified 18 studies comprising 2981 patients. Pooled results revealed that elevated NSE was associated with worse OS (HR = 1.78, 95% CI 1.55-2.06, p < 0.001) and PFS (HR = 1.50, 95% CI 1.16-1.93, p = 0.002). In subgroup analysis, elevated NSE did not predict worse OS in patients who received only chemotherapy (HR 1.22, 95% CI 0.96-1.55, p = 0.10) or part of whom received surgical resection before chemotherapy and radiotherapy (HR = 2.16, 95% CI 0.82-5.69, p = 0.12).
conclusionElevated serum NSE before any therapy of SCLC patients may be a negative prognostic factor for OS and PFS. The prognostic value of NSE for OS was particularly observed in patients treated by standard management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.